Financial Snapshot

Revenue
$788.0M
TTM
Gross Margin
86.97%
TTM
Net Earnings
$163.5M
TTM
Current Assets
Q1 2024
Current Liabilities
Q1 2024
Current Ratio
1381.24%
Q1 2024
Total Assets
Q1 2024
Total Liabilities
Q1 2024
Book Value
$751.8M
Q1 2024
Cash
Q1 2024
P/E
76.87
May 30, 2024 EST
Free Cash Flow
$166.1M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $12.568 Billion

About Shockwave Medical, Inc.

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The company is headquartered in Santa Clara, California and currently employs 1,001 full-time employees. The company went IPO on 2019-03-07. The firm is focused on development and commercialization of products intended to transform the way calcified cardiovascular disease is treated. The company provides care for the treatment of calcified cardiovascular disease through its differentiated local delivery of sonic pressure waves, intravascular lithotripsy (IVL). Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD. Its Shockwave L6 IVL catheter is a six-emitter catheter for use in its IVL System in large diameter vessels for the treatment of PAD. Its Shockwave C2 IVL catheter and Shockwave C2+ IVL catheter are two-emitter catheters for use in its IVL System for the treatment of coronary artery disease (CAD).

Industry: Surgical & Medical Instruments & Apparatus Peers: ABBOTT LABORATORIES ABIOMED INC Envista Holdings Corp GLOBUS MEDICAL INC HOLOGIC INC INSULET CORP MASIMO CORP Penumbra Inc TELEFLEX INC ZIMMER BIOMET HOLDINGS, INC.